(Q34130045)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155848%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

review article

1 reference

title

Monotherapy versus combination therapy for bacterial infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155848%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155848%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

P Muñoz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155848%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 November 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155848%20AND%20SRC:MED&resulttype=core&format=json

Medical Clinics of North America

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155848%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

84

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155848%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155848%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

1357-89, v

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155848%20AND%20SRC:MED&resulttype=core&format=json

Single or Combination Therapy of Staphylococcal Endocarditis in Intravenous Drug Abusers

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The epidemiology of bacterial resistance to quinolones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Antimicrobial Synergism in the Therapy of Gram-Negative Rod Bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Klebsiella endocarditis: report of two cases and review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Susceptibility testing of Listeria monocytogenes. A reassessment of bactericidal activity as a predictor for clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of human brucellosis with doxycycline plus rifampin or doxycycline plus streptomycin. A randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Development of listeriosis during vancomycin therapy in a neutropenic patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Beta-lactam resistance among Escherichia coli and Klebsiella species blood culture isolates in Finnish hospitals. Finnish Study Group for Antimicrobial Resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Vancomycin treatment for enterococcal meningitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Novel method for measurement of outer membrane permeability to new beta-lactams in intact Enterobacter cloacae cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Group A streptococcal bacteremia. A 10-year prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Investigation of a nosocomial outbreak due to Serratia marcescens in a maternity hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Vancomycin-aminoglycoside combinations in therapy of endocarditis caused by Enterococcus species and Streptococcus bovis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Extended-spectrum beta-lactamase producing strains of Enterobacter cloacae transferring resistance to cefotaxime and ceftazidime.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of Listeria bacteremia with vancomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Activity in vitro of 22 antimicrobial agents against clinical isolates of Listeria monocytogenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: focus on ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Klebsiella bacteremia. A 10-year review in a cancer institution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Successful antepartum treatment of listeriosis with vancomycin plus netilmicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

In vitro Activity of Piperacillin/Tazobactam against 615 Pseudomonas aeruginosa Strains Isolated in Intensive Care Units

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Listeria monocytogenes infection in a prosthetic knee joint in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Enterobacter bacteremia. An analysis of 50 episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Brucellar meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Epidemiological study of variations in beta-lactam antibiotic susceptibility of Pseudomonas aeruginosa in two intensive care units

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

In vitro activity of sparfloxacin compared with those of five other quinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Quinupristin/dalfopristin: a review of its activity in experimental animal models of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Susceptibility of beta-hemolytic streptococci to nine antimicrobial agents among four medical centers in Salt Lake City, Utah, USA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Characterization of vancomycin resistance in Enterococcus durans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Listeriosis in bone marrow transplant recipients: incidence, clinical features, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Meropenem treatment of post-traumatic meningitis due to Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945-1977.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Complications associated with Brucella melitensis infection: a study of 530 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Successful treatment of enterobacter meningitis with ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparative review of combination therapy: two beta-lactams versus beta-lactam plus aminoglycoside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The Acylampicillins: Mezlocillin, Piperacillin, and Azlocillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Nosocomial Legionnaires' disease: a global perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Evaluation of gentamicin and penicillin as a synergistic combination in experimental murine listeriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Meropenem: a microbiological overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

beta-Lactam resistance amongst Enterobacter species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ribosomal resistance of clinical enterococcal to streptomycin isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ciprofloxacin as an effective antibacterial agent in serratia endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Klebsiella pneumoniae bacteraemia at an urban general hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Aztreonam in the treatment of gram-negative meningitis and other gram-negative infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Nosocomial pneumonia: comparative multicentre trial between monotherapy with cefotaxime and treatment with antibiotic combinations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Bactericidal activity of meropenem and interactions with other antibiotics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of endocarditis due to Pseudomonas aeruginosa with imipenem.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Netilmicin synergy with carbenicillin or cefamandole against Serratia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Development of resistance by Enterobacter cloacae during therapy of pulmonary infections in intensive care patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

A comparative study on the efficacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Malignant otitis externa: the therapeutic evolution of a lethal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Pseudomonas aeruginosa meningitis treated with ceftazidime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Childhood brucellosis in Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Nosocomial Bacteremia Due to Enterococcus faecalis without Endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

A statistical evaluation of the bactericidal effects of ceftibuten in combination with aminoglycosides and ciprofloxacin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Enterococcal bacteremia: analysis of 75 episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ciprofloxacin (intravenous/oral) versus ceftazidime in lower respiratory tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comprehensive evaluation of ciprofloxacin-aminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The Safety and Efficacy of Clarithromycin in Patients with Legionella Pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Intensive care management of community-acquired Klebsiella pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Epidemiology of Klebsiella bacteraemia: a case control study using Escherichia coli bacteraemia as control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparison of ciprofloxacin and rifampicin in experimental Legionella pneumophila pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Management of listeriosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The enterococcus: "putting the bug in our ears".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Adjunctive antimicrobial therapy for complicated appendicitis: bacterial overkill by combination therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Successful treatment of Pseudomonas ventriculitis with ciprofloxacin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Synergic post-antibiotic effect of amikacin in combination with β-lactam antibiotics on Gram-negative bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Antimicrobial chemotherapy of human infection due to Listeria monocytogenes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Rapidly fatal outcome of bacteremic Klebsiella pneumoniae pneumonia in alcoholics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Pneumonia caused by gram-negative bacilli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Successful use of higher-than-recommended dosage of imipenem in Pseudomonas aeruginosa endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Therapy for experimental endocarditis due to Staphylococcus epidermidis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Failure of treatment of legionella pneumonia with ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Serum bactericidal activity of ceftazidime increased by netilmicin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Detection of Extended Spectrum β-Lactamases inEscherichia coliandKlebsiella pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Resistance of enterococci to aminoglycosides and glycopeptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Teicoplanin in endocarditis: a multicentre, open European study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Listeria infection after liver transplantation: report of a case and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Survey of the prevalence of beta-lactamases amongst 1000 gram-negative bacilli isolated consecutively at the Royal London Hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Quality of antimicrobial susceptibility testing in the UK: a Pseudomonas aeruginosa survey revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Lower respiratory tract infections in the intensive care unit: consequences of antibiotic resistance for choice of antibiotic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Activity of isepamicin and selection of permeability mutants to beta-lactams during aminoglycoside therapy of experimental endocarditis due to Klebsiella pneumoniae CF104 producing an aminoglycoside acetyltransferase 6' modifying enzyme and a TEM-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The Efficacy of Rifampin as Adjunctive Therapy in Selected Cases of Staphylococcal Endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Revised interpretation of oxacillin MICs for Staphylococcus epidermidis based on mecA detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Enterococcal Endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Is amoxicillin-cotrimoxazole the most appropriate antibiotic regimen for listeria meningoencephalitis? Review of 22 cases and the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Rote of the quinolones in the treatment of legionellosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Combination therapy: a way to limit emergence of resistance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ciprofloxacin for Pseudomonas aeruginosa meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Potential role of fluoroquinolones in the treatment of bacterial meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Penetration of aztreonam into cerebrospinal fluid of patients with bacterial meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The specter of glycopeptide resistance: current trends and future considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Vancomycin-resistant enterococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Penicillin-tobramycin synergism against enterococci: a comparison with penicillin and gentamicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

In vitro activity of piperacillin/tazobactam versus other broad-spectrum antibiotics against nosocomial gram-negative pathogens isolated from burn patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Klebsiella bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Acute and chronic adult osteomyelitis and prosthesis-related infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The life and times of the Enterococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Central nervous system infection with Listeria monocytogenes. 33 years' experience at a general hospital and review of 776 episodes from the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Efficacy of meropenem in experimental meningitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Cephalosporins in the treatment of meningitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Trimethoprim-sulfamethoxazole therapy for infective endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of experimental chronic osteomyelitis due to staphylococcus aureus with vancomycin and rifampin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Novel therapies in streptococcal toxic shock syndrome: attenuation of virulence factor expression and modulation of the host response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Lack of resistance to erythromycin, rifampicin and ciprofloxacin in 98 clinical isolates of Legionella pneumophila

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparative activity of piperacillin/tazobactam against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Emergence of resistance after therapy with antibiotics used alone or combined in a murine model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Beta-lactamases and detection of beta-lactam resistance in Enterobacter spp.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Klebsiella pneumoniae pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of experimental endocarditis due to multidrug resistant Enterococcus faecium with ciprofloxacin and novobiocin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Synergy between Carbenicillin and an Aminoglycoside (Gentamicin or Tobramycin) against Pseudomonas aeruginosa Isolated from Patients with Endocarditis and Sensitivity of Isolates to Normal Human Serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of Pseudomonas meningitis with ceftazidime with or without concurrent therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Malignant external otitis: insights into pathogenesis, clinical manifestations, diagnosis, and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of pseudomonal endocarditis with high-dose aminoglycosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Biochemical and physiologic basis for susceptibility and resistance of Pseudomonas aeruginosa to antimicrobial agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Combination antibiotic therapy of bacterial endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

beta-Lactamases of gram-negative bacteria: new challenges for new drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Current antimicrobial therapy of anaerobic infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Epidemics of nosocomial urinary tract infection caused by multiply resistant gram-negative bacilli: epidemiology and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Efficacy of teicoplanin for enterococcal infections: 63 cases and review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ciprofloxacin in the treatment of gram-negative bacillary meningitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Multifocal outbreaks of metallo-beta-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Therapy of experimental murine brucellosis with streptomycin, co-trimoxazole, ciprofloxacin, ofloxacin, pefloxacin, doxycycline, and rifampin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology/oncology patients in Switzerland: a multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta-lactamase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Resistance to cefotaxime and seven other beta-lactams in members of the family Enterobacteriaceae: a 3-year survey in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of human brucellosis with netilmicin and doxycycline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Recognition and optimum treatment of brucellosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The flesh-eating bacterium: what's next?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

In vitro antimicrobial effects of various combinations of penicillin and clindamycin against four strains of Streptococcus pyogenes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Penetration of aztreonam into cerebrospinal fluid and brain of noninfected rabbits and rabbits with experimental meningitis caused by Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Clinical and microbiological evaluation of pefloxacin in lower respiratory tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment options for chronic prostatitis due to vancomycin-resistant Enterococcus faecium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Klebsiella pneumoniae endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Pseudomonas aeruginosa: in vitro susceptibility to antimicrobial drugs, single and combined, with and without defibrinated human blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparative efficacy of ciprofloxacin, ceftazidime and gentamicin, given alone or in combination, in a model of experimental septicemia due to Klebsiella pneumoniae in neutropenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Epidemiological analysis of imipenem-resistant Serratia marcescens in hospitalized patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Long-term oral ciprofloxacin in the treatment of prosthetic valve endocarditis due to Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

An outbreak of Serratia marcescens infections related to contaminated chlorhexidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparison of patients with enterococcal bacteremia due to strains with and without high-level resistance to gentamicin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Enterobacter bacteremia: a review of 58 episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Penicillin and gentamicin therapy for enterococcal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Delayed bactericidal activity of beta-lactam antibiotics against Listeria monocytogenes: antagonism of chloramphenicol and rifampin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

In vitro activities of trimethoprim and sulfamethoxazole against Listeria monocytogenes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Antibiotic therapy for enterobacter meningitis: a retrospective review of 13 episodes and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with high-dose ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Addition of rifampin to carboxypenicillin-aminoglycoside combination for the treatment of Pseudomonas aeruginosa infection: clinical experience with four patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Treatment of experimental endocarditis due to multidrug-resistant Enterococcus faecium with clinafloxacin and penicillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

Epidemiological Spectrum and Current Treatment of Listeriosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Multicenter laboratory evaluation of the bioMérieux Vitek antimicrobial susceptibility testing system with 11 antimicrobial agents versus members of the family Enterobacteriaceae and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

In vitro activities in new oxazolidinone antimicrobial agents against enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

The comparative synergistic activity of amikacin, gentamicin, netilmicin and azlocillin, mezlocillin, carbenicillin and ticarcillin against Serratia marcescens

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Enterobacter bacteremia in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Klebsiella bacteremia: an analysis of 100 episodes

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Resistance to imipenem among selected gram-negative bacilli in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Comparative activities of new fluoroquinolones, alone or in combination with amoxicillin, trimethoprim-sulfamethoxazole, or rifampin, against intracellular Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Survey of extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence of TEM-52 in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Efficacy of oral ciprofloxacin plus rifampin for treatment of malignant external otitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Oral rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Treatment of human brucellosis with doxycycline and gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

Left-sided endocarditis due to Pseudomonas aeruginosa. A report of 10 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2805%2970293-5

7 January 2021

10.1016/S0025-7125(05)70293-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155848%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference